FR2832633B1 - Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete - Google Patents

Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete

Info

Publication number
FR2832633B1
FR2832633B1 FR0115398A FR0115398A FR2832633B1 FR 2832633 B1 FR2832633 B1 FR 2832633B1 FR 0115398 A FR0115398 A FR 0115398A FR 0115398 A FR0115398 A FR 0115398A FR 2832633 B1 FR2832633 B1 FR 2832633B1
Authority
FR
France
Prior art keywords
alkyl
aryl
metformin
oxo
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0115398A
Other languages
English (en)
Other versions
FR2832633A1 (fr
Inventor
Gerard Moinet
Dominique Marais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0115398A priority Critical patent/FR2832633B1/fr
Application filed by LIPHA SAS filed Critical LIPHA SAS
Priority to PL02369894A priority patent/PL369894A1/xx
Priority to EP02787576A priority patent/EP1448181B1/fr
Priority to PT02787576T priority patent/PT1448181E/pt
Priority to ES02787576T priority patent/ES2266605T3/es
Priority to KR10-2004-7006791A priority patent/KR20040058266A/ko
Priority to MXPA04005033A priority patent/MXPA04005033A/es
Priority to AU2002351848A priority patent/AU2002351848A1/en
Priority to HU0402241A priority patent/HUP0402241A2/hu
Priority to DE60211938T priority patent/DE60211938T2/de
Priority to JP2003546870A priority patent/JP2005515984A/ja
Priority to US10/497,145 priority patent/US20050020609A1/en
Priority to CNA028228375A priority patent/CN1592615A/zh
Priority to PCT/EP2002/012355 priority patent/WO2003045368A1/fr
Priority to BR0214487-5A priority patent/BR0214487A/pt
Priority to RU2004119817/15A priority patent/RU2004119817A/ru
Priority to AT02787576T priority patent/ATE327746T1/de
Priority to CA002468280A priority patent/CA2468280A1/fr
Priority to SI200230383T priority patent/SI1448181T1/sl
Priority to DK02787576T priority patent/DK1448181T3/da
Priority to TW091134094A priority patent/TW200300341A/zh
Publication of FR2832633A1 publication Critical patent/FR2832633A1/fr
Priority to ZA200405021A priority patent/ZA200405021B/en
Publication of FR2832633B1 publication Critical patent/FR2832633B1/fr
Application granted granted Critical
Priority to CY20061101178T priority patent/CY1105165T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0115398A 2001-11-28 2001-11-28 Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete Expired - Fee Related FR2832633B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR0115398A FR2832633B1 (fr) 2001-11-28 2001-11-28 Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
RU2004119817/15A RU2004119817A (ru) 2001-11-28 2002-11-06 Фармацевтическая композиция, содержащая метформин в сочетании с 4-оксомасляной кислотой, и их применение для лечения диабета
PCT/EP2002/012355 WO2003045368A1 (fr) 2001-11-28 2002-11-06 Composition pharmaceutique contenant une combinaison de metformine et d'un acide 4-oxobutanoique et son utilisation pour traiter le diabete
ES02787576T ES2266605T3 (es) 2001-11-28 2002-11-06 Composicion farmaceutica que comprende una combinacion de metformin y un acido 4-oxobutanoico y su uso para el tratamiento de la diabetes.
KR10-2004-7006791A KR20040058266A (ko) 2001-11-28 2002-11-06 메트포르민 및 4-옥소부탄산의 조합물을 포함하여이루어지는 약제학적 조성물 및 당뇨병을 치료하기 위한이의 용도
MXPA04005033A MXPA04005033A (es) 2001-11-28 2002-11-06 Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
AU2002351848A AU2002351848A1 (en) 2001-11-28 2002-11-06 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
HU0402241A HUP0402241A2 (hu) 2001-11-28 2002-11-06 Metformin és 4-oxo-butánsav kombinációját tartalmazó gyógyászati készítmény, és a készítmény alkalmazása diabétesz kezelésére
DE60211938T DE60211938T2 (de) 2001-11-28 2002-11-06 Pharmazeutische zusammensetzung enthaltend eine kombination aus metformin und einer 4-oxobutansäure und ihre verwendung zur behandlung von diabetes
JP2003546870A JP2005515984A (ja) 2001-11-28 2002-11-06 メトホルミンと４−オキソブタン酸の組合せを有する薬剤組成物、および糖尿病治療へのその適用
US10/497,145 US20050020609A1 (en) 2001-11-28 2002-11-06 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
CNA028228375A CN1592615A (zh) 2001-11-28 2002-11-06 含有二甲双胍和4－氧代丁酸的药物组合物及其在治疗糖尿病中的用途
PL02369894A PL369894A1 (en) 2001-11-28 2002-11-06 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
PT02787576T PT1448181E (pt) 2001-11-28 2002-11-06 Composicao farmaceutica compreendendo uma combinacao de metformina de um acido 4-oxobutanoico e o seu uso no tratamento da diabetes
BR0214487-5A BR0214487A (pt) 2001-11-28 2002-11-06 Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
AT02787576T ATE327746T1 (de) 2001-11-28 2002-11-06 Pharmazeutische zubereitung enthaltend eine kombination aus metformin und a 4-oxobutanonsäure und ihre verwendung zur behandlung von diabetes
CA002468280A CA2468280A1 (fr) 2001-11-28 2002-11-06 Composition pharmaceutique contenant une combinaison de metformine et d'un acide 4-oxobutanoique et son utilisation pour traiter le diabete
SI200230383T SI1448181T1 (sl) 2001-11-28 2002-11-06 Farmacevtski sestavek, ki obsega kombinacijo metformina in 4-oksobutanojske kisline, ter njegova uporaba za zdravljenje diabetesa
DK02787576T DK1448181T3 (da) 2001-11-28 2002-11-06 Farmaceutisk præparat som omfatter en kombination af metformin og en 4-oxobutansyre og anvendelse deraf til behandling af diabetes
EP02787576A EP1448181B1 (fr) 2001-11-28 2002-11-06 Composition pharmaceutique contenant une combinaison de metformine et d'un acide 4-oxobutanoique et son utilisation pour traiter le diabete
TW091134094A TW200300341A (en) 2001-11-28 2002-11-22 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
ZA200405021A ZA200405021B (en) 2001-11-28 2004-06-24 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
CY20061101178T CY1105165T1 (el) 2001-11-28 2006-08-23 Φαρμακευτικη συνθεση που πepιλαμβανει συνδυασμο μετφορμινης και 4-οξοβουτανικου οξεος και η χρηση αυτης για τη θepαπεια του διαβητη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0115398A FR2832633B1 (fr) 2001-11-28 2001-11-28 Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete

Publications (2)

Publication Number Publication Date
FR2832633A1 FR2832633A1 (fr) 2003-05-30
FR2832633B1 true FR2832633B1 (fr) 2004-09-24

Family

ID=8869889

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0115398A Expired - Fee Related FR2832633B1 (fr) 2001-11-28 2001-11-28 Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete

Country Status (22)

Country Link
US (1) US20050020609A1 (fr)
EP (1) EP1448181B1 (fr)
JP (1) JP2005515984A (fr)
KR (1) KR20040058266A (fr)
CN (1) CN1592615A (fr)
AT (1) ATE327746T1 (fr)
AU (1) AU2002351848A1 (fr)
BR (1) BR0214487A (fr)
CA (1) CA2468280A1 (fr)
CY (1) CY1105165T1 (fr)
DE (1) DE60211938T2 (fr)
DK (1) DK1448181T3 (fr)
ES (1) ES2266605T3 (fr)
FR (1) FR2832633B1 (fr)
HU (1) HUP0402241A2 (fr)
MX (1) MXPA04005033A (fr)
PL (1) PL369894A1 (fr)
PT (1) PT1448181E (fr)
RU (1) RU2004119817A (fr)
TW (1) TW200300341A (fr)
WO (1) WO2003045368A1 (fr)
ZA (1) ZA200405021B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117855A1 (fr) * 2004-06-04 2005-12-15 Kowa Company., Ltd. Médicament pour la prévention ou le traitement du diabète
EP1792580A1 (fr) 2005-09-27 2007-06-06 Ziterion GmbH Implants dentaires en deux parties faites de céramique biocompatible
EP1967157A1 (fr) 2007-03-05 2008-09-10 Ziterion GmbH Implant dentaire hybride bipartite
EP2106767A1 (fr) 2008-03-31 2009-10-07 Ziterion GmbH Implant dentaire bipartite
GB201004058D0 (en) * 2010-03-11 2010-04-28 Consiglio Nazionale Ricerche Diagnostic assay for obesity and related disorders
US20220031636A1 (en) * 2018-09-28 2022-02-03 Societe Des Produits Nestle S.A. Compounds that enhance the action of metformin
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863915A (en) * 1996-05-15 1999-01-26 Bayer Corporation Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide

Also Published As

Publication number Publication date
DE60211938D1 (de) 2006-07-06
US20050020609A1 (en) 2005-01-27
ZA200405021B (en) 2005-05-30
KR20040058266A (ko) 2004-07-03
WO2003045368A1 (fr) 2003-06-05
MXPA04005033A (es) 2004-08-11
JP2005515984A (ja) 2005-06-02
DK1448181T3 (da) 2006-09-04
CA2468280A1 (fr) 2003-06-05
PL369894A1 (en) 2005-05-02
TW200300341A (en) 2003-06-01
HUP0402241A2 (hu) 2005-02-28
EP1448181A1 (fr) 2004-08-25
ES2266605T3 (es) 2007-03-01
FR2832633A1 (fr) 2003-05-30
BR0214487A (pt) 2004-10-19
ATE327746T1 (de) 2006-06-15
EP1448181B1 (fr) 2006-05-31
AU2002351848A1 (en) 2003-06-10
CN1592615A (zh) 2005-03-09
RU2004119817A (ru) 2005-04-20
CY1105165T1 (el) 2010-03-03
DE60211938T2 (de) 2007-05-24
PT1448181E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
JP2011516565A5 (fr)
DE60126947D1 (de) Behandlung der glykogenspeicherkrankheit typ ii
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE448199T1 (de) Verbindungen mit taxol-verstärkender wirkung
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
WO2004029031A3 (fr) Agents therapeutiques utiles dans le traitement de la douleur
ATE387246T1 (de) Mittel zum färben von keratinhaltigen fasern
FR2832633B1 (fr) Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
EP1314719A4 (fr) Derives d'acide benzoique et medicaments possedant ces derniers comme principe actif
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
ATE364586T1 (de) Steigerung der wirksamkeit von wirkstoffen durch micellare zubereitung mit retinolderivaten
SE0002476D0 (sv) New compounds
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
DE502004005055D1 (de) Oxaliplatinlösungskonzentrate
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
BR0112216A (pt) Composto, formulação farmaceutica, métodos para o tratamento de diabetes mellitus tipo ii em um paciente em necessidade do mesmo, para inibir a atividade de irosina fosfatase, para inibir a atividade de ptp-b1 em um mamìfero, de atividade cdc25a em um mamìfero, e uso do composto
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
BRPI0406840A (pt) Derivados de acil-fenil-uréia substituìdos por carbonilamino, processos para a sua preparação e sua aplicação
NZ505994A (en) Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
WO2003032974A3 (fr) Utilisation de derives du sulfamide comme composes pharmaceutiques

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060731